Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 1,544 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Women-Only Clear all
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Messages That Motivate: Communicating Alcohol-Related Breast Cancer Risk to Young Adult Women

NCT07802054
View directory record Official record
Conditions
Communication, Message Perception, Alcohol, Cancer Prevention, Behavior, Risk
Interventions
Risk Message, Efficacy Message, Industry Deception, YAW Susceptibility, Mechanisms
Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 23, 2026, 6:11 PM EDT
Recruiting Not applicable Interventional

Hormone-free Antral Retrieval for Viable Embryo Storage & Transfer

NCT07801105
View directory record Official record
Conditions
Infertility
Interventions
CAPA-IVM System, Serial Unstimulated Transvaginal Oocyte Retrieval, ICSI, Blastocyst Culture, PGT-A, Embryo Vitrification/Accumulation, and Single Euploid Embryo Transfer
Device · Procedure
Lead sponsor
Kevin Doody
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bedford, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 23, 2026, 6:11 PM EDT
Active, not recruiting Phase 1 Interventional

Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder

NCT05223829
View directory record Official record
Conditions
PTSD, Alcohol Use Disorder
Interventions
Brexanolone
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Ascending and Repeated Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TS-142 in Healthy Participants

NCT04464239
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TS-142, TS-142 Placebo
Drug
Lead sponsor
Taisho Pharmaceutical R&D Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 23, 2026, 6:11 PM EDT
Not listed Phase 2 Interventional

Brief Intervention to Reduce Drinking and Intimate Partner Violence in Women

NCT00539812
View directory record Official record
Conditions
Intimate Partner Violence, Substance Use
Interventions
Standard Care, Brief Alcohol Intervention combined with standard care
Behavioral
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
Female only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Oct 23, 2026, 6:11 PM EDT
Recruiting No phase listed Observational

A Study of Prucalopride in Breastfeeding Women With Constipation

NCT04838522
View directory record Official record
Conditions
Chronic Idiopathic Constipation (CIC)
Interventions
No Intervention
Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Phase 1 Interventional

A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems

NCT06692322
View directory record Official record
Conditions
Liver Diseases, Healthy
Interventions
Zongertinib (BI 1810631)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Dietary Intervention to Modify Breast Milk Content in Obese Lactating Women

NCT03744429
View directory record Official record
Conditions
Effect of Diet on Breast Milk Composition
Interventions
Mediterranean Diet
Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study Of PF-04427429 In Healthy Women Volunteers

NCT01511497
View directory record Official record
Conditions
Pain, Migraine Disorders
Interventions
PF-04427429, Normal saline
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
3
States / cities
Miami, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days

NCT01145768
View directory record Official record
Conditions
Healthy
Interventions
TC-5214, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Results available

Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial

NCT04344860
View directory record Official record
Conditions
Von Willebrand Diseases, Postpartum Hemorrhage
Interventions
Recombinant Von Willebrand factor, Tranexamic Acid Injection [Cyklokapron]
Drug
Lead sponsor
Nicoletta C Machin
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 23, 2026, 6:11 PM EDT
Withdrawn No phase listed Observational

Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer

NCT00329017
View directory record Official record
Conditions
Breast Cancer
Interventions
Fine needle aspiration
Procedure
Lead sponsor
Carol Fabian, MD
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of AC0058TA in Healthy Male and Female Subjects

NCT02847325
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AC0058TA, Placebo capsules
Drug
Lead sponsor
ACEA Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Oct 23, 2026, 6:11 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants

NCT07075640
View directory record Official record
Conditions
Healthy Participants
Interventions
AG-236, Placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing the Safety and Tolerability of a Single IV Dose of AZD9742 in Healthy Elderly Male and Female Subjects

NCT01154621
View directory record Official record
Conditions
Tolerability, Healthy, Elderly
Interventions
AZD9742, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
65 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 3, 2010 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study of Sotagliflozin in Subjects With Hepatic Impairment

NCT02471274
View directory record Official record
Conditions
Hepatic Impairment, Healthy
Interventions
sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
4
States / cities
Lakewood, Colorado • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100

NCT01135680
View directory record Official record
Conditions
Drug Toxicity
Interventions
HPN-100, HPN-100 or Placebo, Placebo, Moxifloxacin
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 45 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids

NCT03197623
View directory record Official record
Conditions
Osteopenia, Osteoporosis, Osteonecrosis
Interventions
LLP2A-ALENDRONATE, Placebo
Drug
Lead sponsor
Nancy E. Lane, MD
Other
Eligibility
20 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Cypress, California • Walnut Creek, California • Duncansville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Oct 23, 2026, 6:11 PM EDT
Terminated Phase 4 Interventional Results available

Comparison of Combination Therapy vs Single Agent Therapy for Treatment of Urge Incontinence.

NCT02176642
View directory record Official record
Conditions
Urinary Urge Incontinence
Interventions
Oxybutynin extended release, Posterior Tibial Nerve Stimulation, Placebo
Drug · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants

NCT07502417
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Ethinyl Estradiol + Levonorgestrel, ABBV-722
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Phase 2 Interventional Results available

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

NCT03056755
View directory record Official record
Conditions
Breast Cancer
Interventions
Alpelisib, Fulvestrant, Letrozole, Goserelin, Leuprolide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
25
States / cities
Gilbert, Arizona • Phoenix, Arizona • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD5847 After Multiple Doses Over 14 Days

NCT01116258
View directory record Official record
Conditions
Healthy
Interventions
AZD5847, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2010 · Synced Oct 23, 2026, 6:11 PM EDT
Terminated Phase 2 Interventional Results available

Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer

NCT01776008
View directory record Official record
Conditions
Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Akt Inhibitor MK2206, Anastrozole, Goserelin Acetate, Laboratory Biomarker Analysis, Neoadjuvant Therapy, Pharmacological Study, Therapeutic Conventional Surgery
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
8
States / cities
Scottsdale, Arizona • Chicago, Illinois • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Early Phase 1 Interventional

RANKL Inhibition and Breast Tissue Biomarkers

NCT03629717
View directory record Official record
Conditions
Breast Cancer Prevention, Mammographic Density
Interventions
Ultrasound-guided core needle biopsy, Denosumab, Blood draw, Calcium, Vitamin D
Procedure · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
35 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 23, 2026, 6:11 PM EDT